Form 8-K - Current report:
SEC Accession No. 0001564590-21-008821
Filing Date
2021-02-25
Accepted
2021-02-25 16:07:10
Documents
14
Period of Report
2021-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dvax-8k_20210225.htm   iXBRL 8-K 33033
2 EX-99.1 dvax-ex991_24.htm EX-99.1 322847
3 GRAPHIC gqcfqtvb3nwq000001.jpg GRAPHIC 6265
  Complete submission text file 0001564590-21-008821.txt   512128

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA dvax-20210225.xsd EX-101.SCH 5772
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20210225_lab.xml EX-101.LAB 19478
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20210225_pre.xml EX-101.PRE 11627
7 EXTRACTED XBRL INSTANCE DOCUMENT dvax-8k_20210225_htm.xml XML 3558
Mailing Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 21680290
SIC: 2834 Pharmaceutical Preparations